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Introduction
Urinary tract infections (UTIs) are among the most 
common bacterial infections in humans (Bischoff et al. 
2018). It is estimated that 40% of women and 12% of 
men experience a minimum one symptomatic UTI 
episode during their lifetimes, and 27 to 48% of the 
affected women suffer from recurrent UTIs (Braum-
baugh et al. 2013; Micali et al. 2014). UTIs comprise 
about 40% of all hospital-acquired infections and 50% 
of bacterial infections that contribute to increased mor-
bidity causing prolonged hospitalization (Asadi Karam 
et al. 2019). UTIs are also an economic problem. In the 
United States, about 11 million people per year have 
been treated due to UTIs, generating the cost of about 
$6 billion (Mann et al. 2017). Healthcare-associated 
infections (HAI) are a serious threat for patients in 
terms of morbidity and mortality, with the healthcare-
associated urinary tract infections (HAUTI) being 
among the most frequent HAI. In Europe, HAUTI 
account for 19.0% of all HAI (ECDCP 2013). Commu-
nity- or healthcare-acquired UTIs are clinically divided 
into complicated or uncomplicated, and among many 
other factors, this classification determines what anti-
microbial agents can be applied for treatment (Zacchè 
and Giarenis 2016). Complicated UTIs require pro-
longed therapy and occur in patients with renal fail-
ure, anatomical urinary tract abnormalities such as 
urinary obstruction and retention or in patients that 
use medical devices such as a catheter. Complicated 
UTIs are also associated with immunosuppression 
and previous antibiotic exposure. This category of UTIs 
increases the risk of chronic and/or recurrent infec-
tions. Uncomplicated UTIs are found in patients who 
have no anatomical urinary tract abnormalities and do 
not use the urinary tract instrumentation. In uncom-
plicated UTIs, host immune response may successfully 
fight infection without antibiotic therapy (Mann et al. 
2017). The symptomatic UTIs are classified as uro- 
sepsis, pyelonephritis (infection of the upper UTI) or 
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Urinary tract infections (UTIs) belong to the most common community-acquired and nosocomial infections. A main etiological factor 
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cystitis (infection of the lower UTI) (Terlizzi et al. 2017) 
(Fig. 1). The presence of numerous UPEC cells in the 
urine (≥ 105 CFU/ml) without the clinical symptoms is 
called asymptomatic bacteriuria (ABU) and in healthy 
non-pregnant women is not treated in 20–80% of cases 
(Schneeberger et al. 2014).
The increase of antibiotic resistance and appearance 
of multi-drug resistant (MDR) pathogens in the course 
of UTI is related to high rates of inadequate antibiotic 
empirical therapies prescribed without the antibiotic 
susceptibility testing and finally result in an ineffective 
UTI treatment (Adamus-Białek 2018). Wagenlehner 
et al. (2016) showed that among 27 542 patients from 
856 urology units in 70 countries, 56% of the hospital-
ized patients were treated with antimicrobials. Among 
them, 46% received prophylactic antibiotic treatment, 
26% of them had the antimicrobials prescribed for the 
microbiologically proven UTI, 21% − for suspected UTI, 
and 7% for other infections. The above study also has 
revealed that broad-spectrum antibiotics were applied 
such as fluoroquinolones (35%), cephalosporins (27%), 
and penicillins (16%). The results obtained by Cek et al. 
(2014) showed the correlation between the increased 
use of broad-spectrum antibiotics and increased anti-
microbial resistance and multi-resistance of bacteria. 
These authors also observed that prophylactic antibio-
tic treatment of urological patients occurred most fre-
quently in Asia, Africa, and Latin America (86%, 85%, 
and 84%, respectively), followed by Europe (67%). The 
increasing number of MDR isolates from UTIs of out-
patients makes treatment more difficult. Risk factors 
of MDR isolated from UTIs include prior use of anti- 
microbials, hospitalization, genitourinary disturbances, 
age, and recurrent UTIs (Walker et al. 2016). Tenney 
et al. (2018) have recently analyzed the published data 
(25 studies including 31 284 patients with the confirmed 
UTI) to determine the risk factors for MDR isolated 
from UTIs and revealed that previous antibiotic treat-
ment applied from 2 to 365 days earlier was the most 
commonly identified risk factor. The analysis by Tenney 
et al. (2018) showed also that urinary catheterization, 
previous hospitalization, and residence in a nursing 
home were strong risk factors of MDR isolated from 
UTI. Present work aimed to review the available litera-
ture published in 2016–2019 to investigate the preva-
lence of UPEC resistant to antibiotics recommended for 
the treatment of UTIs. The resistance to antibiotics of 
UPEC isolated in different regions of the world (Euro-
pean countries, North America, Asia, and some coun-
tries of Africa) was compared. The increase of resistance 
to fluoroquinolones, which was significantly higher in 
developing countries than in developed countries, has 
been revealed. Also, the resistance mechanisms identi-
fied in these pathogens were discussed.
Escherichia coli as a main etiological agent
of UTIs
The bacteria belonging to the Enterobacteriaceae 
such as Klebsiella pneumoniae (about 7%), Proteus mira­
bilis (about 5%), Citrobacter, Enterobacter, and other 
bacteria such as Pseudomonas aeruginosa, Acinetobacter 
baumannii, Staphylococcus aureus, Staphylococcus 
sapro phiticus, Enterococcus faecalis, Streptococcus bovis, 
and the fungus Candida albicans can cause UTIs (Hof 
Fig. 1. Classification of urinary tract infections (Bartoletti et al. 2016).
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2017; Mann et al. 2017). However, among the bacterial 
species involved in UTIs, uropathogenic Escherichia coli 
strains (UPEC) are the most common. UPEC account 
for about 80% of uncomplicated UTIs, 95% of commu-
nity-acquired infections, and 50% of hospital-acquired 
infections (Tabasi et al. 2016). UPEC also remains the 
most frequent pathogen in complicated UTIs (Bartoletti 
et al. 2016).
UPEC is a heterogeneous group of extraintestinal 
pathogenic E. coli (ExPEC) that seem to originate from 
the gut. Many studies suggest that farm animals may 
be reservoirs of E. coli strains carrying virulence genes 
responsible for UTI in humans. Comparison of the 
antimicrobial resistance profiles and genetic virulence 
determinants in the E. coli strains isolated from UTI 
patients, farm animals or meat (particularly chicken) 
showed high similarity (Jakobsen et al. 2010; Mellata 
et al. 2018). Food-borne urinary tract infections (FUTI) 
include UTIs acquired from bacteria-contaminated food 
(Nordstrom et al. 2013). ExPEC can survive in the ali-
mentary tract but do not cause diseases of the digestive 
system. However, ExPEC strains present in other sites 
such as central nervous system, blood or the urinary 
tract may cause serious illness. Four main UPEC phy-
logroups (A, B1, B2, and D) were identified based on 
the genomic Pathogenicity Islands (PAI) occurrence and 
strains belonging to B2 and D groups are isolated most 
frequently from UTI (Kot et al. 2016; Asadi Karam et al. 
2019). The intestinal E. coli enters the urinary tract sys-
tem and colonizes the periurethral and vaginal areas and 
the urethra. After that, bacteria reach the bladder and 
attach to the surface epithelium using fimbrial and non-
fimbrial adhesins (Mann et al. 2017). Adhering bacte-
ria may be internalized into the uroepithelial facet cells, 
and then they can enter the cytoplasm, replicate and 
form intracellular bacterial communities (IBCs) being 
a  source of quiescent intracellular reservoirs (QIRs) 
(Asadi Karam et al. 2019). The host immune system 
may remove some of the IBCs by exfoliation of bladder 
surface facet cells and excreting them with the urine but 
the remaining bacteria can grow as a biofilm resistant to 
immune mechanisms and antibacterial agents (McLel-
lan and Hunstad 2016). Some of these bacteria escape 
from the biofilm, convert to motile form and dissemi-
nate into the bladder lumen or even ascend into the kid-
neys, causing pyelonephritis (Flores-Mireles et al. 2015). 
UPEC may also spread from the urinary tract to the 
bloodstream causing bacteremia. For 15% to 23% of epi-
sodes of UTI positive blood cultures could be obtained 
(Velasco et al. 2003; Bahagon et al. 2007; van Nieuwkoop 
et al. 2010). The results presented by Abernethy et al. 
(2017) suggest that treatment failure in UTIs, as well as 
an inappropriate use and management of urinary cath-
eters in the hospital and community, are important risk 
factors for the development of E. coli bacteremia.
Treatment of UTIs
Based on the general European susceptibility pat-
terns and according to the European Association of 
Urology guidelines, the following antimicrobial agents 
are recommended for treatment of uncomplicated 
cystitis in premenopausal women and uncomplicated 
pyelonephritis in all European countries: nitrofuran-
toin, fosfomycin trometamol and trimethoprim-sul-
famethoxazole (TMP-SMZ) (Bartoletti et al. 2016). 
Nitrofurantoin and fosfomycin trometamol are recom-
mended as first-line therapy for uncomplicated cysti-
tis (Bonkat et al. 2017; Asadi Karam et al. 2019). TMP-
SMZ is not indicated as the empirical treatment due to 
the high prevalence of bacterial resistance and can be 
considered only for the patients with a low prevalence 
of resistant E. coli (< 20%) (Bartoletti et al. 2016; Bonkat 
et al. 2017). Fluoroquinolones (ciprofloxacin and levo-
floxacin) play an important role in the treatment of 
more severe infections and septicemia, and thus, cipro-
floxacin should be considered as an alternative, not as 
a first-line antibiotic, in the treatment of uncomplicated 
cystitis (Bartoletti et al. 2016). Ciprofloxacin could be 
used as second-line empiric therapy in cases of mild and 
moderate pyelonephritis or complicated UTI treatment, 
and as third-line empiric treatment for uncomplicated 
cystitis. Amoxicillin-clavulanic acid is recommended as 
first line-therapy for mild and moderate pyelonephri-
tis or complicated UTI, as well as alternative empiric 
therapy for uncomplicated cystitis. For complicated 
UTI (high fever, sepsis, vomiting) or severe pyelo-
nephritis, amoxicillin with gentamicin or a second-
generation cephalosporin with an aminoglycoside are 
recommended as first-line empiric therapy, and third-
generation cephalosporin applied intravenously as 
alternative empiric therapy (Bonkat et al. 2017; Cheung 
et al. 2017). The choice of antimicrobials for the treat-
ment of UTI is also based on local resistance profiles 
of the pathogen.
Antimicrobial resistance of UPEC
UTIs are associated with significant use of anti-
biotics that cause implications for bacterial ecology 
and spread of resistance to antibiotics, especially when 
it stems from the empirical antimicrobial treatment of 
recurrent UTIs. Antimicrobial resistance in UPEC and 
the spreading of MDR UPEC in recent decades is a clin-
ical problem, particularly in women with recurrent 
UTIs. The increasing frequency of MDR UPEC, espe-
cially in developing countries, results in excessive use of 
broad-spectrum antibiotics such as fluoroquinolones, 
cephalosporins, and aminoglycosides that raise the cost 
of treatment and hospitalization (Bartoletti et al. 2016; 
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Sanchez et al. 2016). Antimicrobial resistance between 
UPEC is increasing in many countries and shows the 
time- and area-related variability (Fig. 2).
Resistance to nitrofurantoin
According to the European Association of Urology 
guidelines (Bonkat et al. 2017), nitrofurantoin is recom-
mended for the treatment of uncomplicated cystitis as 
first-line empiric therapy. At present, the resistance of 
UPEC to nitrofurantoin is very low, favoring its use as 
a  first-line antibacterial agent. A retrospective analy-
sis performed by Sanchez et al. (2016) showed that in 
the United States nitrofurantoin retains a high level of 
antibiotic activity against urinary E. coli. A  compari-
son of the reports from the period of 2003 to 2012 
revealed that resistance of E. coli isolates from adults 
to nitrofurantoin only slightly increased (from 0.7% 
to 0.9%). The rates of UPEC resistance in Germany, 
Belgium, and Spain in 2013–2014 were below 1.5% 
(Kresken et al. 2016). A slightly higher percentage of 
UPEC resistant to nitrofurantoin was observed among 
isolates from elderly hospitalized patients in Argentina 
(2.3%) (Delpech et al. 2018). While in Brazil the rate 
of UPEC isolates resistant to nitrofurantoin was 6.6% 
(Cunha et al. 2016). In European countries (Roma-
nia, Poland, France) the percentage of nitrofurantoin 
resistant UPEC isolated from outpatients and hospi-
talized patients ranged from 3% to 3.8% (Ciontea et al. 
2018; Kot et al. 2016; Lavigne et al. 2016). The study 
concerning E. coli resistance rates at urology clinics 
in the Netherlands revealed that nitrofurantoin was 
active against 95% of strains (van der Donk et al. 2012). 
Among UPEC from inpatients and outpatients in Bos-
nia and Herzegovina, 8.23% isolates were resistant to 
nitrofurantoin (Abduzaimovic et al. 2016). Lack of sus-
ceptibility to nitrofurantoin among E. coli isolates from 
the urine of patients hospitalized in different hospitals 
in England was low (4.6–6.9%) (Abernethy et al. 2017). 
E. coli strains isolated from the hospitalized patients 
with UTIs in Mongolia (Munkhdelger et al. 2017), 
Pakistan (Ali et al. 2016), and Iran (Raeispour and 
Ranjbar 2018) showed that 5.4%, 6%, and 10% of strains 
were resistant to this antimicrobial agent, respectively. 
The study conducted by Prasada et al. (2019) in India 
showed that the resistance of UPEC isolated from 
hospitalized patients to nitrofurantoin was 13.3% and 
did not significantly change over 5 years (2013–2017). 
A similar rate of UPEC resistance to nitrofurantoin 
(12.7%) in Mexico was reported by Ramírez-Castillo 
et al. (2018). These results show that nitrofurantoin 
remains the drug of choice for the treatment of uncom-
plicated cystitis, although it should not be used for 
the treatment of pyelonephritis since its concentra- 
tion in the renal parenchyma is too low. Additional 
Fig. 2. The resistance of UPEC to antimicrobials using in the treatment of UTIs.
Amoxicillin-clavulanic acid; the developed countries (USA, 3.1–40%; Germany, 5.3%; Poland, 13.9%; England, 30%; France, 37.6%), developing 
countries (Nepal, 48%; Pakistan, 71%; Jordan, 83%). Ciprofloxacin; developed countries (USA, 5.1–12.1%; Belgium, 12.9%; Germany, 10.5–17.3%; 
Switzerland.17.4%; England, 20.4%; France, 24.8%; Spain, 39.8%), developing countries (Jordan, 55.5%, Mongolia, 58.1%; Pakistan, 60.8%; Nepal, 
64.6%; Ethiopia, 85.5%). Trimethoprim-sulfamethoxazole; developed countries (Belgium, 14.6%; USA, 17.4%; Germany, 18.45%; Poland, 21.4%; 
Switzerland, 24.5%; Spain, 30.9%; France, 37.1%), developing countries (Iran, 54%; Mexico, 66%; Ethiopia, 68.5%; Mongolia, 70.9%; Jordan, 73,1%; 
Pakistan, 82%).
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characteristics, as high efficiency, cost-effectiveness, 
and weak adverse environmental impact suggest that 
nitrofurantoin should be the first-choice treatment in 
uncomplicated UTI in women.
Resistance to fosfomycin
Fosfomycin is an “old” antibiotic used for the treat-
ment of drug-resistant bacterial infections. Fosfomycin 
shows activity against several Enterobacteriaceae spe-
cies, including those expressing extended-spectrum 
β-lactamases (ESBL) and metallo-β-lactamases (MBL). 
Fosfomycin is currently approved for use in some Euro-
pean countries as a single 3 g dose for treating uncom-
plicated UTIs caused by E. coli in women (Dijkmans 
et al. 2017). The results of Hirsch et al. (2015) showed 
that all E. coli strains investigated were susceptible to 
fosfomycin. The comparative study on UPEC suscep-
tibility to fosfomycin conducted in Germany, Belgium, 
and Spain, showed that only < 1.5% of isolates were 
resistant to this antibiotic (Kresken et al. 2016). In UTI 
caused by non-resistant uropathogens, clinical cure 
rates ranged from 87% to 93%, while microbiological 
cure rates ranged from 80% to 83%. The treatments of 
UTIs caused by MDR uropathogens with fosfomycin 
demonstrated an overall microbiological cure rate of 
59% (Neuner et al. 2012). Antibacterial efficacy of fos-
fomycin is weaker compared to other first-line agents 
used in the treatment of uncomplicated UTIs, and thus 
this drug should be avoided if there is a suspicion of 
early pyelonephritis.
Resistance to trimethoprim-sulfamethoxazole
TMP-SMZ is another important and widely used 
first-line antimicrobial in the treatment of uncompli-
cated cystitis. The comparative study performed in the 
USA by Yamaji et al. (2018) showed that frequencies 
of TMP-SMZ resistance in UPEC isolates obtained 
from outpatients with UTI symptoms in 1999–2000 
and in 2016–2017 did not significantly change (resist-
ance slightly increased from 16.9% to 17.1%). However, 
increasing resistance to this drug has recently been was 
observed in many countries. A majority of studies show 
resistance at or above the accepted level of 20%, and 
thus TMP-SMZ should not be used in empiric treat-
ment (Bartoletti et al. 2016). High resistance rate to 
TMP-SMZ (24.5%) among E. coli isolated from urine 
in 2012–2015 was reported in Switzerland by Erb et al. 
(2018). The considerable geographic and age-related 
differences in resistance of UPEC to TMP-SMZ were 
observed, and the highest resistance was noted in cer-
tain regions of Europe in young women. Studies of 
TMP-SMZ activity against UPEC revealed resistance 
in European countries (Belgium, Germany, Poland, 
Switzerland, France, Spain, Bosnia and Herzegovina, 
and Romania) between 14.6% and 60% (Abduzaimovic 
et al. 2016; Kot et al. 2016; Kresken et al. 2016; Lavigne 
et al. 2016; Ciontea et al. 2018; Erb et al. 2018; Hitzen-
bichler et al. 2018). The TMP-SXT resistance rate in 
India in 2013 was 52%, and in 2017 it increased up 
to 59.6% (Prasada et al. 2019). A similar rate of resist-
ance of UPEC isolates against TMP-SXT (50.6%) was 
observed in Brazil (Cunha et al. 2016). The activity of 
TMP-SMZ against UPEC in other regions of the world 
was significantly lower as the frequencies of TMP-SMZ 
resistant UPEC isolates ranged from 72.7% in Mexico 
to 82% in Pakistan (Ali et al. 2016; Ramírez-Castillo 
et al. 2018). High resistance to TMP-SMZ was also 
observed in Iran (54%), Ethiopia (68.5%), Mongolia 
(70.9%), and Jordan (73,1%) (Raeispour and Ranjbar 
2016; Munkhdelger et al. 2017; Regasa Dadi et al. 
2018; Shakhatreh et al. 2018). These results indicate 
that in many countries TMP-SMZ should not be used 
in empiric UTI therapy due to the high frequency of 
UPEC resistant to this antimicrobial.
Resistance to fluoroquinolones
Fluoroquinolones (FQs) are recommended for 
empirical oral antimicrobial therapy in uncompli-
cated pyelonephritis (Bonkat et al. 2017) and they are 
frequently used for the treatment of UTIs (Drekonja 
et al. 2013; Yamasaki et al. 2015; Walker et al. 2016). 
The increasing emergence of E. coli resistant to FQs was 
reported worldwide, and it has emerged probably due 
to the excessive use of these antibiotics. The resistance 
of UPEC to FQs was reported from different countries 
and the level of resistance is significant. The results of 
Prasada et al. (2019) revealed a -high rate of fluoroqui-
nolone resistance in UPEC in India (> 60%). The results 
of the meta-analysis on resistance to ciprofloxacin in 
the community- and hospital-acquired UTIs showed 
that UPEC resistance to ciprofloxacin was higher in 
the hospital when compared to the community set-
ting (Fasugba et al. 2015). In Europe, resistance to FQs 
was reported in 22% of strains, and the prevalence of 
fluoroquinolone-resistant UPEC strains was about 31% 
among hospitalized patients in the United States (Asadi 
Karam et al. 2019). In many parts of the world, > 20% of 
E. coli isolated from patients with community-acquired 
uncomplicated UTI and > 50% of E. coli isolated from 
complicated UTI showed resistance to FQs (Talan et al. 
2016). In Poland, resistance to FQs was observed in 
about 30% of UPEC (Michno et al. 2018). MDR UPEC 
demonstrated much higher rates of resistance to FQs, 
ranging from 49% to 72% (Walker et al. 2016). Among 
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FQs, ciprofloxacin is the most commonly prescribed 
for UTIs because it is available in oral and intravenous 
preparations. In the group of UPEC strains isolated in 
2013–2014 from outpatients in Brasilia, 18.8% were 
resistant to ciprofloxacin, and resistance to ciprofloxa-
cin was associated with multidrug resistance (Moreira 
da Silva et al. 2017). In the United States in the period 
from 2013 to 2014, 12.1% of E. coli isolates from 
patients with acute uncomplicated and complicated 
pyelonephritis were resistant to this antibiotic (Talan 
et al. 2016). A similar percentage of UPEC resistant to 
ciprofloxacin was noted in other research conducted 
in the United States in 2016–2017 for isolates from the 
urine samples from outpatients with symptoms of UTI 
(Yamaji et al. 2018). While a higher rate of resistance 
to ciprofloxacin was detected in UPEC from elderly 
hospitalized patients in Argentina (42.8%) (Delpech 
et al. 2018), and in UPEC isolates from the community 
and hospital-acquired infections in Mexico (47.3%) 
(Ramírez-Castillo et al. 2018). Blaettler et al. (2009) 
found that in Switzerland, over 10 years (1997–2007), 
resistance to ciprofloxacin increased significantly from 
1.8% to 15.9%, which coincided with an increase in cip-
rofloxacin use in this country. In 2000 in Switzerland 
FQs were prescribed for treatment of uncomplicated 
UTIs in 64% of cases. In the recent study conducted 
in Switzerland in 2012–2015, an increase of resistance 
to ciprofloxacin from 15.9% (Blaettler et al. 2009) to 
17.4% (Erb et al. 2018) was reported. Although total 
antibiotic usage in Switzerland is lower than in other 
European countries, the fluoroquinolone consumption 
in this country for treatments of urological outpatients 
comprises 20.1% of all antibiotics (Helsana 2014) and it 
is rather high when compared to an average of 7.3% in 
other European countries (Filippini et al. 2004), which 
may explain the increasing fluoroquinolone resistance 
in UPEC isolates. In 2013–2014 in Belgium, Germany, 
and Spain the percentage of ciprofloxacin-resistant 
UPEC strains was 12.9, 17.3, and 39.8%, respectively 
(Kresken et al. 2016). The research conducted in Eng-
land showed that among E. coli isolates from the urine 
samples from patients, who later developed bacteremia, 
20.4% and 15.5% of isolates were resistant to ciprofloxa-
cin in the year and four weeks before the bacteremia 
onsets. (Abernethy et al. 2017). Resistance to ciproflox-
acin was significantly higher in developing countries 
(Ethiopia – 85.5%, Nepal – 64.6%, Pakistan – 60.8%, 
Mongolia – 58.1%, Jordan – 55.5%) (Ali et al. 2016, 
Khatri et al. 2017; Munkhdelger et al. 2017; Regasa Dadi 
et al. 2018; Shakhatreh et al. 2018) than in developed 
countries (USA – 5.1%, Germany –  10.5%, Switzer-
land – 17.4%, France – 24.8%) (Lavigne et al. 2016; Erb 
et al. 2018; Hitzenbichler et al. 2018; Yamaji et al. 2018). 
The study conducted in Switzerland showed also that 
patient age over 65  years was associated with higher 
E. coli resistance to ciprofloxacin (Erb et al. 2018). 
According to many authors, the widespread use of fluo-
roquinolones in the outpatients is the cause of the con-
tinuous increase in resistance to this drug. Therefore, 
ciprofloxacin should be avoided in first-line treatment 
of UTIs and be used only in more severe infections or 
as an alternative when the recommended agents cannot 
be used. Restrictions of ciprofloxacin usage should be 
enhanced especially in developing countries, where no 
regulations concerning the use of this antibiotic cur-
rently apply (Asadi Karam et al. 2019).
Resistance to amoxicillin-clavulanic acid
Amoxicillin-clavulanic acid was recommended as 
first-line therapy for mild and moderate pyelonephritis 
or complicated UTI or as an alternative empiric ther-
apy for uncomplicated cystitis (Cheung et al. 2017). 
Resistance rates for amoxicillin-clavulanic acid vary 
regionally. In the United States in 2012, the prevalence 
of UPEC isolates resistant to this antibiotic in the age 
groups: below 17, 18–64, and over 65 years were 3.1%, 
3.9%, and 5.5%, respectively (Sanchez et al. 2016). 
Morrill et al. (2017) studied E. coli urinary isolates col-
lected in the period from 2009 to 2013 from inpatients 
and outpatients in the Veterans Affairs Care System in 
the United States and showed that rates of resistance 
to amoxicillin or ampicillin/beta-lactamase inhibitors 
were approximately 40%. Ramírez-Castillo et al. (2018) 
have recently found that 23.6% of UPEC isolates were 
resistant to amoxicillin-clavulanic acid in Mexico. The 
resistance rate to amoxicillin-clavulanic acid among 
E. coli isolates from the urine samples taken from 
patients of tertiary care hospital in Germany in 2015–
2017 was 5.3% (Hitzenbichler et al. 2018). Between 
2015 and 2017 in Romania, (Ciontea et al. 2018), and 
in Bosnia and Herzegovina in 2016, 29.0% and 19.6% of 
UPEC isolates collected from outpatients were resistant 
to amoxicillin-clavulanic acid (Abduzaimovic et al. 
(2016). In Poland in women with uncomplicated UTIs 
3.3% of UPEC were resistant to amoxicillin-clavulanic 
acid in 2003–2006 (Naber et al. 2008). In 2007–2008 
the percentage of amoxicillin-clavulanic acid-resistant 
UPEC isolated from hospital-acquired UTIs in Poland 
was 13.9% (Kot et al. 2016). In the group of UPEC 
isolates obtained in 2009–2010 in the urology units 
in France, 37.6% were resistant to this antimicrobial 
(Lavigne et al. 2016) Among UPEC isolated in Argen-
tina from patients over 70 years old with UTIs, with-
out urinary catheters and antimicrobial therapy, 28.6% 
were resistant to this antibacterial agent (Delpech et al. 
2018). In England, 30% of E. coli isolates from the urine 
samples from hospitalized patients showed resistance 
to amoxicillin-clavulanic acid (Abernethy et al. 2017). 
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High level of resistance to this antimicrobial was 
reported for UPEC isolates from children hospitalized 
in 2015–2016 in Nepal (48%) (Parajuli et al. 2017), and 
in Pakistan in the group of UPEC isolated from outpa-
tients (71%) (Ali et al. 2016). While very high resist-
ance to amoxicillin-clavulanic acid (83%) was showed 
for UPEC isolates from hospitalized patients in Jordan 
(Shakhatreh et al. 2018). These results demonstrate that 
the levels of UPEC resistance to amoxicillin-clavulanic 
acid varied between geographical regions or patient 
populations. For this reason, the empiric regimens for 
uncomplicated and complicated UTIs should be guided 
by the local susceptibility of E. coli. However, definitive 
regimens should be developed according to the suscep-
tibility results of UPEC, when available.
Resistance to other antibiotics
Some UPEC isolates can be resistant to ampicillin 
and first-generation oral cephalosporins (Moya-Dion-
isio et al. 2016). The resistance to cefuroxime (second-
generation cephalosporin) in Belgium, Germany, 
and Spain was 5.5%, 12.8%, and 16.6%, respectively 
(Kresken et al. 2016). E. coli isolates from the urine sam-
ples from hospitalized patients in England were found 
to be resistant (13.8–21.3%) to third-generation ceph-
alosporins (cefotaxime/ceftazidime) (Abernethy et al. 
2017). The percentage of UPEC susceptible to third 
generation cephalosporins in Romania was 87% (Cion-
tea et al. 2018). While, the other research conducted in 
this country demonstrated that the resistance rate was 
47.52% for ampicillin, and 41.16% for tetracycline (Cri-
stea et al. 2019). The resistance of E. coli isolates from 
the urinary tract isolated in the urology department 
in France to amoxicillin, ticarcillin, nalidixic acid was 
high and reached 61.4%, 59%, and 31.9%, respectively 
(Lavigne et al. 2016). In Iran, the resistance to ampicil-
lin, ceftazidime and nalidixic acid was higher than 50%, 
while amikacin and gentamicin showed high activity 
against UPEC (89.1% and 82.4% of sensitive isolates, 
respectively) (Faghri et al. 2016). The resistance against 
gentamicin and amikacin of UPEC isolated from out-
patients in Pakistan was 29%, and 4%, respectively (Ali 
et al. 2016). In Mexico, the resistance rates to antibiotics 
belonging to aminoglycosides were 28.2%, 19.1%, 10%, 
and 5.5% for gentamycin, tobramycin, amikacin, and 
netilmicin, respectively (Ramírez-Castillo et al. 2018). 
The carbapenems, piperacillin-tazobactam, and ami-
kacin were highly active (> 95% susceptibility) against 
E. coli isolates from UTIs collected from 2010 to 2014 
in Canada and the United States (Lob et al. 2016). Car-
bapenems (ertapenem, imipenem, meropenem, dorip-
enem) are recommended for the treatment of acute 
uncomplicated pyelonephritis, complicated UTI, and 
urosepsis (Bonkat et al. 2017). Shahbazi et al. (2018) 
showed that all UPEC isolates from patients with UTI 
in Teheran were negative for carbapenemases. Another 
study on UPEC isolates from Iran confirmed a lack of 
resistance to meropenem in isolates from outpatients 
and inpatients (Faghri et al. 2016). Ali et al. (2016) 
described a  high activity of meropenem in Pakistan 
since only 1.3% of UPEC were resistant to this anti-
biotic. However, a recent study from Saudi Arabia about 
the presence of carbapenem-resistant uropathogenic 
E. coli clones in community-acquired UTIs reported 
the occurrence of carbapenemases NDM-1 and 5 (the 
New Delhi metallo-lactamase), and carbapenemases 
of the OXA-181 type in these strains (Abd El Ghany 
et al. 2018). The emergence of carbapenem-resistant 
uropathogenic E. coli isolates makes treatment of these 
infections increasingly challenging.
Mechanisms of UPEC resistance to antibiotics
Resistance to β-lactams is related to the production 
of different types of β-lactamase enzymes. Among the 
genes often located on plasmids are those coding mul-
tiple types of β-lactamases (bla genes) (Adamus-Białek 
et al. 2018). β-lactamases hydrolyze the amide bond of 
the four- membered β-lactam ring of β-lactam anti-
biotics (penicillin, cephalosporin, monobactams, and 
carbapenems) (Noyal et al. 2009). ESBL are enzymes 
that confer resistance to β-lactam antibiotics (all peni-
cillins, cephalosporins, and monobactams), except for 
carbapenems, cephamycins, and β-lactamase inhibi-
tors (Baudry et al. 2009). ESBL are the predominant 
source of Enterocacteriaceae resistance to 3rd- and 
4th-generation cephalosporins and they developed as 
a result of mutations in the genes coding for ancestral 
enzymes blaTEM-1, blaTEM-2, and blaSHV-1 (Dashti 
et al. 2006). Three classes of β-lactamases including 
TEM and SHV, and since 2000 a new group of ESBL, 
CTX-M (cefotaximases), were observed among ESBL 
produced by UPEC (Ojdana et al. 2014; Shahbazi et al. 
2018). Genetic analyses of UPEC from hospitalized 
patients in different hospital wards in Lodz (Poland) 
revealed that TEM-1 was present in almost all inves-
tigated strains (Adamus-Białek et al. 2018). Among 
UPEC isolated from 2013 to 2015 from patients hos-
pitalized in a  Department of Internal Medicine and 
Nephrology in southern Poland, 8% of the strains 
produced ESBL (Michno et al. 2018). In France, 7.6% 
of UPEC produce ESBL with the predominance of 
CTX-M (Lavigne et al. 2016). The CTX-M enzymes 
are active against cefotaxime and ceftriaxone and less 
active against ceftazidime (Bhat et al. 2012). UPEC pro-
ducing ESBL are particularly often detected in develop-
ing countries (Iran – 37.1%, Nepal – 38.9%, Pakistan 
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– 40%, and Jordan – about 50%) (Ali et al. 2016; Parajuli 
et al. 2017; Shakhatreh et al. 2018). Prasada et al. (2019) 
revealed that in India the percentage of ESBL-produc-
ing UPEC increased from 45.2 to 59.6% over 5 years 
(2013–2017). The frequency of ESBL-producing E. coli 
isolates is different in various parts of the world and 
sometimes even in various hospitals within the country. 
In addition to resistance to β-lactam antibiotics, ESBL-
producing E. coli isolates are also resistant to other anti-
microbial agents, such as aminoglycosides, tetracycline, 
and trimethoprim/sulfamethoxazole (Rezai et al. 2015). 
Shahbazi et al. (2018) has found that higher number 
of ESBL-producing UPEC isolates were resistant to 
amino glycosides and quinolones when compared to the 
UPEC strains that not produce ESBL. Carbapenems 
(imipenem and meropenem) represent the best option 
for the treatment of UTIs caused by ESBL-producing 
strains (Idil et al. 2016). Cephalosporins, penicillins, 
and monobactams should be used with β-lactamase 
inhibitors (Bartoletti et al. 2016).
Quinolones and fluoroquinolones are extensively 
used worldwide in the treatment of UTIs and their 
common use led to increased resistance in UPEC. The 
mechanism of fluoroquinolone action is based on bind-
ing to and impeding the activity of topoisomerase  II 
(DNA gyrase) and topoisomerase IV (parC and parE) 
(Komp Lindgren et al. 2003). DNA gyrase is encoded by 
the gyrA and gyrB genes (Pourahmad Jaktaji and Mohiti 
2010). The resistance of E. coli to quinolones frequently 
results from a mutation in the gyrA and gyrB genes that 
catalyze DNA supercoiling. The point mutations in gyrA 
protein N-terminal sequence (amino acids 67 (Ala-67) 
to 106 (Gln-106)) strongly correlate with phenotypic 
resistance to quinolones and fluoroquinolones, and this 
sequence is named a quinolone resistance-determining 
region (QRDR) (Friedman et al. 2001). Investigation 
of mutations in codons 83 and 106 of the gyrA gene in 
UPEC isolates in Iran presented the significant relation-
ship between mutations in the gyrA gene and quinolone 
and fluoroquinolone resistance pattern of UPEC iso-
lates (Shenagari et al. 2018). Other genes responsible 
for the resistance to quinolones and fluoroquinolones 
are the qnr genes (qnrA, qnrB, and qnrC), being the 
most important PMQR (plasmid-mediated quinolone 
resistance) genes that induce antibiotic resistance by 
inhibition of binding of quinolones to DNA gyrase and 
topoisomerases (Shahbazi et al. 2018).
Other mechanisms of E. coli resistance to quinolo-
nes and fluoroquinolones are related to the presence of 
efflux pumps and decreased uptake of the antibiotics 
due to changes in the outer membrane porin proteins 
(Asadi Karam et al. 2019). Abdelhamid and Abozahra 
(2017) showed that the increased expression of the 
efflux pump-coding genes acrA and mdfA was related to 
the growing resistance to levofloxacin, which confirms 
that efflux pump systems contribute to fluoroquinolone 
resistance in urinary E. coli isolates.
The mechanism of fosfomycin action is unique 
because it irreversibly inhibits an early stage of bacte-
rial cell wall biosynthesis, leading to bacterial cell lysis 
and death (Dijkmans et al. 2017). The active transport 
proteins used to transport both glucose-6-P and glyc-
erol-3-P are also used by fosfomycin to reach bacte-
rial cytoplasm (Popovic et al. 2010). Fosfomycin in the 
cytoplasm is an analog of phosphoenolpyruvate (PEP) 
and binds UDP-GlcNAc enolpyruvyl transferase, inacti-
vating this enzyme, which is essential for peptidoglycan 
biosynthesis. The resistance to fosfomycin is due to three 
mechanisms that have already been described. One of 
them is based on decreased uptake of fosfomycin by the 
bacterial cells due to mutations in the genes that encode 
the glycerol-3-phosphate transporter or the glucose-
6-phosphate transporter (Kadner and Winkler 1973; 
Tsuruoka and Yamada 1975). The second mechanism 
is based on point mutations in the binding site of UDP-
GlcNAc enolpyruvyl transferase (Kim et al. 1996). The 
third mechanism of resistance is related to the inactiva-
tion of fosfomycin by enzymatic cleavage of the oxirane 
ring of the antibiotic or by phosphorylation of the phos-
phonate group. The opening of the oxirane ring may be 
catalyzed by glutathione transferase (FosA), L-cysteine 
thiol transferase (Fos B) or fosfomycin-specific epoxide 
hydrolase (FosX) (Rigsby et al. 2005).
Nitrofurantoin is recommended for the treatment 
of uncomplicated cystitis and, currently, the resistance of 
UPEC to nitrofurantoin is very low. Resistance to nitro-
furantoin did not evolve as fast as to other drugs because 
of this antimicrobial acts at multiple targets in the bac-
terial cell (Veeraraghavan and Shakti 2015). Sandegren 
et al. (2008) identified mutations conferring resistance 
to nitrofurantoin and found that the mutation frequency 
is approximately 10−7/cell in E. coli. The mutations in 
the nsfA and nfsB genes that encode oxygen-insensitive 
nitroreductases were responsible for nitrofurantoin 
resistance. It was also found that the growth of bacte-
rial cells in the presence of nitrofurantoin at therapeutic 
concentrations was greatly reduced in nitrofurantoin-
resistant mutants. It may indicate that resistant mutants 
in the presence of nitrofurantoin were probably unable 
to establish an infection (Sandegren et al. 2008).
The resistance of UPEC lineages
The multilocus sequence-typing (MLST) technique 
is widely used to study ExPEC lineages. Sequence types 
(STs) 10, 69, 73, 95, 127, and 131 defined by MLST 
were isolated as pandemic clones of ExPEC from 
human infections, including UTIs and bloodstream 
infections (Tartof et al. 2005; Adams-Sapper et al. 2013; 
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Riley 2014). Globally, these genotypes account for more 
than 50% of ExPEC infections (Gibreel et al. 2012; 
Adams-Sapper et al. 2013; Kallonen et al. 2017). The 
isolates belonging to the lineage ST131 are multidrug-
resistant (Banerjee and Johnson 2014; Petty et al. 2014). 
Adams-Sapper et al. (2013) who investigated E. coli iso-
lates from bloodstream infections in the United States, 
found that ST131 was the most common genotype, 
including 92% of multidrug-resistant isolates. UPEC 
isolates from patients in the Northwest region of Eng-
land that belonged to lineage ST131 exhibited higher 
levels of antibiotic resistance when compared to ST127 
isolates that were the most widely susceptible to anti-
biotics (Gibreel et al. 2012). The UPEC of ST131 line 
from a tertiary care hospital in Saudi Arabia was also 
significantly associated with high levels of antibiotic 
resistance and 60% of ST131 carried CTX-M-14 and 
CTX-M-15 (Alghoribi et al. 2015). ST73 was the line-
age most frequently identified by Kallonen et al. (2017) 
among isolates associated with bacteremia in England, 
and isolates belonging to this lineage were susceptible 
to most antibiotics. The authors suggested that drug 
resistance was not a primary determinant for the prev-
alence of E. coli lineages responsible for invasive dis-
eases, and the frequency of E. coli lineages is associated 
with the presence of new lineages outside the hospital. 
Yamaji et al. (2018) compared the clonal distribution 
of UPEC in the same community during two periods. 
The UPEC strains belonging to ST 95, 127, 73, 69, 131, 
and 10 were responsible for 56% of UTI cases in 1999–
2000. In the period 2016–2017, the same STs caused 
64% of UTI cases. The study of Yamaji et al. (2018) 
showed that 46.4% of the isolates resistant to ampicil-
lin in 2016–2017 belonged to four genotypes (ST 95, 
127, 73, and 131), while in 1999–2000 they comprised 
only 21.8%. The increase of resistance to ampicillin was 
observed only in these genotypes. Yamaji et al. (2018) 
reported that ST69 included the highest percent-
age of TMP-SMZ-resistant isolates during two study 
periods. In 2016–2017, 58% of ciprofloxacin-resistant 
isolates represented the ST131 lineage. ST69, 127, and 
131 comprised 70% of isolates with CTX-M. Among 
E. coli extraintestinal isolates from Iran, the high-
est rates of the multidrug-resistance phenotype were 
detected in ST131 (85.7%), and ST69 (41.7%) lineages 
(Hojabri et al. 2019). Similarly to the results by Yamaji 
et al. (2018), the resistance to TMP-SMZ was detected 
mainly in the ST69 lineage. The widespread occurrence 
of new multidrug-resistant E. coli clonal group ST1193 
has recently been demonstrated in the United States 
(Tchesnokova et al. 2019). This clonal group of strains 
was isolated from younger adults. ST1193 isolates were 
resistant to fluoroquinolones and often co-resistant to 
TMP-SXT and tetracycline, but currently, remain sus-
ceptible to most β-lactam antibiotics.
Conclusion
The antibiotic therapy is important in the UTI treat-
ment but in recent years it is becoming more challeng-
ing due to increasing resistance of UTIs to routinely 
applied antibiotics. High resistance of UPEC to FQs 
used as third-line empiric treatment for therapy of 
uncomplicated cystitis in pyelonephritis or second-
line empiric treatment in complicated UTI requires 
a  rational policy of prescription of these drugs. The 
awareness of the resistance rates of E. coli in a given area 
and the established guidelines for appropriate first-line 
antibiotic treatment should be critical in the empirical 
treatment of UTIs, especially for the controlled use of 
fluoroquinolones.
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